Table 4 Univariate sensitivity analysis: when the cost per NIPT is €150 or €76
Screening strategy | 1st and 2nd trimester screening (current screening) | NIPT as contingent testing | NIPT as first-line testing |
|---|---|---|---|
Effectiveness | |||
No of women undergoing 1st and 2nd trimester screening tests | 66,799 | 66,799 | 1336 |
No of women undergoing NIPT | 0 | 3152 | 66,799 |
No of NIPT with a positive result | 0 | 251 | 280 |
No of ITa | 3275 | 579 | 700 |
No of procedure-related miscarriages | 23 | 4 | 5 |
No of T21 cases detected | 271 | 269 | 296 |
Costs | |||
1st and 2nd trimester screening tests | €5,292,716 | €5,292,716 | €101,536 |
NIPT = €150 | €0 | €491,550 | €10,940,400 |
NIPT = €76 | €0 | €249,052 | €5,543,136 |
IT | €3,093,565 | €546,923 | €661,220 |
Hospitalisation due to amniotic fluid leakage and pregnancy termination owing to T21 | €515,591 | €469,362 | €518,389 |
Total costs when NIPT = €150 | €8,901,872 | €6,800,551 | €12,221,545 |
Total costs when NIPT = €76 | €8,901,872 | €6,558,053 | €6,824,281 |
Economic analysis | NIPT as first-line testing vs 1st and 2nd trimester screening | NIPT as contingent testing vs 1st and 2nd trimester screening | NIPT as first-line testing vs NIPT as contingent testing |
|---|---|---|---|
Incremental cost when TPNI = €150 | €3,319,673 | €− 2,101,321 | €5,420,994 |
Incremental cost when TPNI = €76 | €− 2,077,591 | €− 2,343,819 | €266,228 |
Incremental effectiveness (T21 extra cases detected) | 25 | − 2 | 27 |
ICER (€/case T21 extra detected) when NIPT = €150 | 132,787 | – | 200,777 |
ICER (€/case T21 extra detected) when NIPT = €76 | Dominant | – | 9860 |